NCT01619410

Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections

Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this pilot study, the objective is to determine the prevalence of asymptomatic carriage of S. aureus in patients with ABSSSIs and minor cutaneous abscesses after therapy with either linezolid or clindamycin at 40 days after the completion of therapy. Secondarily, the investigators will assess the efficacy of linezolid vs. clindamycin in the empiric therapy of ABSSSIs and minor cutaneous abscesses, as well as the genotypic spectrum of S. aureus isolates causing ABSSSIs or minor cutaneous abscesses and colonization in the target patient population before and after therapy. Given the results of a recent study on linezolid and vancomycin and the investigator's own experience, it is hypothesized that persistent MRSA carriage will be less common after therapy with linezolid for ABSSSIs and minor cutaneous abscesses than it is with oral clindamycin.

Conditions

• Skin Diseases, Bacterial
• Abscess

Interventions

Type	Name	Description
BIOLOGICAL	Linezolid	Linezolid 600 mg every 12 hours for 7 days
BIOLOGICAL	Clindamycin	Clindamycin 300 mg po every 6 hours for 7 days

Timeline

• Start date: 2012-01-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2012-06-14
• Last updated: 2019-11-08
• Results posted: 2019-07-24

Locations

2 sites across 1 country: United States